Literature DB >> 20222890

A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice.

M Dryden1, A T Andrasevic, M Bassetti, E Bouza, J Chastre, G Cornaglia, S Esposito, G French, H Giamarellou, I C Gyssens, D Nathwani, S Unal, A Voss.   

Abstract

Although the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) varies across Europe, healthcare-associated MRSA infections are common in many countries. Despite several national guidelines, the approach to treatment of MRSA infections varies across the continent, and there are multiple areas of management uncertainty for which there is little clinical evidence to guide practice. A faculty, convened to explore some of these areas, devised a survey that was used to compare the perspectives of infection specialists from across Europe on the management of MRSA infections with those of the faculty specialists. The survey instrument, a web-based questionnaire, was sent to 3840 registered delegates of the 19th European Congress of Clinical Microbiology and Infectious Diseases, held in April 2009. Of the 501 (13%) respondents to the survey, 84% were infection/microbiology specialists and 80% were from Europe. This article reports the survey results from European respondents, and shows a broad range of opinion and practice on a variety of issues pertaining to the management of minor and serious MRSA infections, such as pneumonia, bacteraemia, and skin and soft tissue infections. The issues include changing epidemiology, when and when not to treat, choice of treatment, and duration and route of treatment. The survey identified areas where practice can be improved and where further research is needed, and also identified areas of pan-European consensus of opinion that could be applied to European guidelines for the management of MRSA infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20222890     DOI: 10.1111/j.1469-0691.2010.03135.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

1.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

2.  Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals.

Authors:  R A Seaton; S Johal; J E Coia; N Reid; S Cooper; B L Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-31       Impact factor: 3.267

3.  Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs).

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-18       Impact factor: 3.267

4.  Efficacy of Early Oral Switch with β-Lactams for Low-Risk Staphylococcus aureus Bacteremia.

Authors:  Olivia Bupha-Intr; Tim Blackmore; Max Bloomfield
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

5.  Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center.

Authors:  Sminil N Mahajan; Jharna N Shah; Ray Hachem; Frank Tverdek; Javier A Adachi; Victor Mulanovich; Kenneth V Rolston; Issam I Raad; Roy F Chemaly
Journal:  Oncologist       Date:  2012-06-15

6.  Rapid identification of Staphylococcus aureus directly from Bactec blood culture broth by the BinaxNOW S. aureus test.

Authors:  Qinfang Qian; Karen Eichelberger; James E Kirby
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

Review 7.  Commercial Essential Oils as Potential Antimicrobials to Treat Skin Diseases.

Authors:  Ané Orchard; Sandy van Vuuren
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-04       Impact factor: 2.629

8.  Plasma and Intrapulmonary Pharmacokinetics, and Dosage Regimen Optimization of Linezolid for Treatment of Gram-Positive Cocci Infections in Patients with Pulmonary Infection After Cerebral Hemorrhage.

Authors:  Yongli Wei; He Zhang; Maowu Fu; Rui Ma; Ronghui Li; Lingti Kong
Journal:  Infect Drug Resist       Date:  2022-04-08       Impact factor: 4.003

Review 9.  Dalbavancin for the treatment of acute bacterial skin and skin structure infections.

Authors:  Sheena Ramdeen; Helen W Boucher
Journal:  Expert Opin Pharmacother       Date:  2015-08-04       Impact factor: 3.889

Review 10.  A case study on Staphylococcus aureus bacteraemia: available treatment options, antibiotic R&D and responsible antibiotic-use strategies.

Authors:  Annelie A Monnier; Evelina Tacconelli; Christine Årdal; Marco Cavaleri; Inge C Gyssens
Journal:  JAC Antimicrob Resist       Date:  2020-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.